1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

ViroPharma forges ahead with C Diff preventative

 
• By Gemma Sharman

ViroPharma has initiated a Phase II dose-ranging clinical study in North America of VP 20621, its drug to prevent recurrences of Clostridium difficile infection in adults previously treated with antibiotics.

ViroPharma has initiated a Phase II dose-ranging clinical study in North America of VP 20621, its drug to prevent recurrences of Clostridium difficile infection in adults previously treated with antibiotics.

VP 20621 is a non-toxin producing C difficile spore preparation, which acts as a probiotic. The aim is to colonise...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapeutic Category

Incyte’s Povorcitinib Wins Stack Up, Will It Be Enough To Hedge Jakafi Loss?

 
• By Aakash Babu

With patent expiry for its blockbuster blood cancer drug Jakafi on the horizon, Incyte will need to translate these povorcitinib wins from clinic to market.

Regeneron’s Garetosmab May Become Second Drug For Rare Bone Disease FOP

 
• By Alaric DeArment

The company announced positive Phase III data for the drug in fibrodysplasia ossificans progressiva, as well as Phase II combination data among patients with obesity.

Roivant Sets The Stage For Commercial Return With Brepocitinib Data

 
• By Jessica Merrill

Positive Phase III data positions Roivant to launch the oral TYK2/JAK1 inhibitor for dermatomyositis, with an NDA filing planned in early 2026.